Monday, March 4, 2024
HomeFunding Cambridge-based Apollo Therapeutics Secures USD 33.5M in a Second close of...

[Funding alert] Cambridge-based Apollo Therapeutics Secures USD 33.5M in a Second close of its Series C Round Funding

Apollo Therapeutics, a Cambridge, Massachusetts-based company, closed its Series C round of funding with USD 33.5 million. Patient Square Capital led the $260 million round, in which several new investors, including M&G plc and two of the biggest US public pension plans, joined forces with existing investors, including Rock Springs Capital.

Apollo Therapeutics, a Cambridge, Massachusetts-based company, closed its Series C round of funding with USD 33.5 million. Patient Square Capital led the $260 million round, in which several new investors, including M&G plc and two of the biggest US public pension plans, joined forces with existing investors, including Rock Springs Capital.

The company plans to use the funds to licence or purchase more clinical stage programmes that satisfy stringent selection criteria, advance pipeline programmes through clinical development, and further fund its drug discovery and development activities based on advances in basic medical research made at its partner institutions.

Read also – London-based Olsam Group Acquired Dwarfs

Apollo Therapeutics is a portfolio biopharmaceutical company led by Dr. Richard Mason, the CEO, that focuses on turning basic medical research into pharmaceuticals.

A centralised management team of capital allocators and functional leaders with extensive backgrounds in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development forms the foundation of the portfolio-model. This team is then leveraged over a wide range of therapeutic programmes, each of which is overseen by an experienced and committed asset leader.

Read also – GLORY to Acquire Flooid

About Apollo Therapeutics

Apollo Therapeutics, As a portfolio biotech, they generate value for our investors, patients, and inventors by working on a wide range of drug programmes. Their goal is to create a diverse clinical-stage portfolio of assets with a concentration on high-value markets. In their three main biological focus areas—immunology, cell stress response, and cell signaling—they offer more than 20 programmes.

Read also – London-based Labrys Technologies Secures $5.5M in Seed Funding

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular